Obagi has reported positive results of 12-week study comparing CLENZIderm Serum Gel to a combination prescription benzoyl peroxide (BPO)/clindamycin product.
In this multicenter, investigator-blind, randomized, split-face study, CLENZIderm Serum Gel showed a significant reduction in non-inflammatory lesions in week one, said the company.
The study enrolled 65 patients, out of which 23 received four weeks of treatment and 42 received 12 weeks of treatment.
Reportedly, the data showed that patients with moderate facial acne vulgaris experienced significantly greater reductions in non-inflammatory lesions when using the CLENZIderm Serum Gel, as compared to the topical BPO/clindamycin product.
Leon Kircik, investigator and physician, skin care in Kentucky, said: The use of CLENZIderm Serum Gel in this study resulted in faster onset of results, showing a greater reduction in non-inflammatory lesions in weeks one through four. In treating a disease like acne that can cause significant emotional distress, I want to treat my patients with a product that I know will give them rapid improvement. Results of the study also showed continued improvement through week 12 with the use of CLENZIderm Serum Gel.